New research from Eli Lilly suggests that pairing a blockbuster GLP-1 weight-loss drug with an existing psoriasis treatment could trigger a wider range of biological changes than the psoriasis medication alone, offering a potential new avenue for patients who struggle with both conditions.
The findings, released as part of a company-sponsored study, focused on adults with moderate-to-severe psoriasis who also had obesity. Patients received either Taltz (ixekizumab), a standard IL-17 inhibitor, or Taltz combined with Zepbound (tirzepatide), the company's GLP-1/GIP receptor agonist that has become a top-selling treatment for type 2 diabetes and obesity.
By week 36, researchers observed that the combination group showed significantly greater shifts in biomarkers tied to psoriasis severity, immune function, and metabolic health. Specifically, the dual therapy was linked to increases in 482 proteins and 467 genes, compared with just 140 proteins and 16 genes in the Taltz-only arm.
Dr. Mark Genovese, senior vice president of Lilly Immunology Development, said the results underscore a possible link between immune and metabolic systems. “People living with psoriasis and obesity carry a compounded burden that extends beyond what is visible, yet these conditions are too often viewed through separate treatment lenses,” he said. “The broader biomarker changes observed with Taltz and Zepbound, including those associated with skin clearance, may point to a meaningful relationship between immune and metabolic biology.”
Interestingly, the combination also produced an increase in inflammatory immune activity compared with Taltz alone. While that might sound counterintuitive, researchers suggest it reflects a more comprehensive immune response that could contribute to better skin clearance over time.
Dr. James G. Krueger of The Rockefeller University, a leading psoriasis researcher, said the analysis “provides new insights into the potential connected immune and metabolic biology in people with psoriasis and obesity.”
The study adds to a growing body of evidence that GLP-1 therapies may have effects beyond weight loss. As doctors warn about coverage gaps for chronic conditions, the potential for combination therapies to address multiple comorbidities could become a policy issue. Nearly 61 percent of Americans with psoriasis also have overweight or obesity and at least one obesity-related comorbidity, according to the data, which highlights the scale of the problem.
For patients, the findings could eventually lead to new treatment protocols that simultaneously target skin inflammation and metabolic dysfunction. However, researchers caution that more work is needed to confirm whether the biomarker changes translate into meaningful clinical outcomes.
Eli Lilly has been investing heavily in expanding the use of its GLP-1 drugs, including exploring combinations with other therapies. The company's push comes as price transparency rules and broader healthcare debates intensify, with policymakers scrutinizing drug costs and access.
The study was presented at a medical conference and has not yet been peer-reviewed, but it adds to the momentum behind GLP-1 therapies. As the pharmaceutical industry races to develop next-generation obesity treatments, the potential for these drugs to help with inflammatory diseases like psoriasis could open up new markets—and new questions about affordability and insurance coverage.
